UNIRISCO’s support is crucial for DIVERSA, as their strategic investment will not only serve as a catalyst for our growth, but will also strengthen our position to lead in the field of nanomedicine.
DIVERSA Technologies
Spin-off of the Santiago de Compostela Health Research Institute (IDIS) and SERGAS, at the forefront of biotechnology and nanomedicine. The result of years of research, this company commercializes a patented technology of lipid nanosystems that act as carriers of drugs and therapeutic biomolecules, such as messenger RNA, peptides and proteins, protecting them and directing them to their site of action, and therefore increasing their effectiveness and safety. .
Diversa offers its technology to third parties, through co-development agreements with biotechnology and pharmaceutical companies, and distributing the technology in reagent format for researchers. It thus seeks to generate a ‘butterfly effect‘ to catalyze the development of innovative nanomedicines for a wide spectrum of medical applications.